The MIT Center for Integrative Synthetic Biology will create the therapeutics of the future by integrating systems biology and synthetic biology. Systems biology, synthetic biology, and fundamental research in health-related applications are three major disciplines that have thrived in the last decade. These fields have pushed the frontiers of biomedical science with the development of high-throughput platforms for generating and analyzing systems-level data, unprecedented abilities to engineer biological systems, and significant advances in our understanding of the molecular mechanisms underlying human disease. However, due to the diverse expertise required in each discipline, these efforts have been largely independent from each other. Therefore there is a significant opportunity for the integration of systems biology, synthetic biology, and health-related applications in a single research center. Our core group of researchers at MIT is poised to spearhead efforts to overcome these challenges with the MIT Center for Integrative Synthetic Biology. A key feature of the proposed Center is our focus on interdisciplinary and collaborative research into next-generation therapeutics. Our major disease-related targets revolve around Cancer, Diabetes, and Infectious Diseases. Together systems biology and synthetic biology will contribute to significant advances in health-related applications. By integrating top-down systems views of disease with bottom-up synthetic construction of novel treatments, this community will create new disease therapies with the ability to integrate multiple inputs and deliver specific interventions. Numerous synergies in synthetic biology, systems biology, and health-related applications will be generated by the MIT Center for Integrated Synthetic Biology which would be difficult to achieve via solely independent investigator-led research efforts.

Public Health Relevance

Next-generation therapeutics for important diseases constitute the central thrusts of the MIT Center for Integrative Synthetic Biology. Our target areas include Cancer, Diabetes, and Infectious Diseases. All research efforts in the Center will be integrated into these three disease thrusts, which will bring together an interdisciplinary team of systems biologists, synthetic biologists, biomedical researchers, and clinicians.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Specialized Center (P50)
Project #
1P50GM098792-01A1
Application #
8368114
Study Section
Special Emphasis Panel (ZGM1-CBCB-3 (SB))
Program Officer
Gerratana, Barbara
Project Start
2013-09-25
Project End
2018-05-31
Budget Start
2013-09-25
Budget End
2014-05-31
Support Year
1
Fiscal Year
2013
Total Cost
$2,349,998
Indirect Cost
$725,482
Name
Massachusetts Institute of Technology
Department
Engineering (All Types)
Type
Schools of Engineering
DUNS #
001425594
City
Cambridge
State
MA
Country
United States
Zip Code
02139
Anderson, Lisa A; Islam, M Ahsanul; Prather, Kristala L J (2018) Synthetic biology strategies for improving microbial synthesis of ""green"" biopolymers. J Biol Chem 293:5053-5061
Walczak, Marta; Ganesan, Suresh M; Niles, Jacquin C et al. (2018) ATG8 Is Essential Specifically for an Autophagy-Independent Function in Apicoplast Biogenesis in Blood-Stage Malaria Parasites. MBio 9:
Farzadfard, Fahim; Lu, Timothy K (2018) Emerging applications for DNA writers and molecular recorders. Science 361:870-875
Cella, Federica; Wroblewska, Liliana; Weiss, Ron et al. (2018) Engineering protein-protein devices for multilayered regulation of mRNA translation using orthogonal proteases in mammalian cells. Nat Commun 9:4392
Gam, Jeremy J; Babb, Jonathan; Weiss, Ron (2018) A mixed antagonistic/synergistic miRNA repression model enables accurate predictions of multi-input miRNA sensor activity. Nat Commun 9:2430
Li, Yinqing; Weiss, Ron (2017) A Modular Approach to Building Complex Synthetic Circuits. Methods Mol Biol 1651:231-248
Cleto, Sara; Lu, Timothy K (2017) An Engineered Synthetic Pathway for Discovering Nonnatural Nonribosomal Peptides in Escherichia coli. MBio 8:
Shah, Rushina; Del Vecchio, Domitilla (2017) Signaling Architectures that Transmit Unidirectional Information Despite Retroactivity. Biophys J 113:728-742
Kong, David S; Thorsen, Todd A; Babb, Jonathan et al. (2017) Open-source, community-driven microfluidics with Metafluidics. Nat Biotechnol 35:523-529
de la Fuente-Nunez, Cesar; Torres, Marcelo Dt; Mojica, Francisco Jm et al. (2017) Next-generation precision antimicrobials: towards personalized treatment of infectious diseases. Curr Opin Microbiol 37:95-102

Showing the most recent 10 out of 58 publications